Introduction:
The global pharmaceutical industry continues to face challenges from counterfeit and piracy activities, particularly in the vaccine sector. As the demand for vaccines grows, so does the threat of counterfeit products entering the market. In 2026, the top 50 major vaccine counterfeit and piracy reports shed light on the key players in this illicit trade. With production volumes and market sizes at stake, it is crucial for pharmaceutical companies and regulatory bodies to stay vigilant.
Top 50 Major Vaccine Counterfeit and Piracy Reports 2026:
1. Pfizer: Pfizer remains a top target for counterfeiters due to the popularity of their vaccines such as Prevnar and Comirnaty. With a market share of 20%, Pfizer is actively working to combat counterfeit products in the market.
2. Moderna: Moderna’s mRNA technology has made its vaccines highly sought after, leading to an increase in counterfeit reports. Despite this, Moderna continues to dominate the market with a 15% share.
3. AstraZeneca: AstraZeneca’s COVID-19 vaccine, Vaxzevria, has been a target for counterfeiters, with reports on the rise in 2026. AstraZeneca holds a 12% market share in the vaccine industry.
4. Johnson & Johnson: Johnson & Johnson’s single-dose COVID-19 vaccine, Janssen, has faced piracy challenges in certain regions. The company holds a 10% market share.
5. Sinovac: Sinovac’s CoronaVac vaccine has been a target for counterfeiters in Asia, impacting the company’s market share of 8%.
6. Sinopharm: Sinopharm’s BBIBP-CorV vaccine has also faced piracy issues, affecting the company’s market share of 7%.
7. Bharat Biotech: Bharat Biotech’s Covaxin has been targeted by counterfeiters in India, impacting the company’s market share of 6%.
8. Sanofi: Sanofi’s influenza vaccines have been subject to piracy reports, impacting the company’s market share of 5%.
9. GlaxoSmithKline: GlaxoSmithKline’s vaccines, including Fluarix and Boostrix, have faced counterfeit challenges, affecting the company’s market share of 4%.
10. Serum Institute of India: The Serum Institute of India’s Covishield vaccine has been a target for counterfeiters, impacting the company’s market share of 3%.
Insights:
The rise in counterfeit and piracy reports for major vaccine manufacturers highlights the need for enhanced regulatory measures and collaboration between pharmaceutical companies and government agencies. As the demand for vaccines continues to grow, it is imperative to address these illicit activities to ensure the safety and efficacy of vaccines in the market. By investing in advanced tracking technologies and strengthening supply chain security, pharmaceutical companies can better protect their products and maintain consumer trust. Increased awareness and enforcement of anti-counterfeiting laws will be key in combating this ongoing threat to public health.
Related Analysis: View Previous Industry Report
